Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;13:10075–10085. doi: 10.2147/OTT.S262909

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Fan et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Prognostic significance of SNX20, PD-L1, and clinicopathologic parameters. (A) The overall survival curve of responders to PD-1 inhibitors compared with non-responders to PD-1 inhibitors. (B) The overall survival curve of high expression of SNX20 compared with low expression of SNX20 to PD-1 inhibitors. (C) The overall survival curve of high expression of PD-L1 compare with low expression of PD-L1 to PD-1 inhibitors. (D) Effects of SNX20 and PD-L1 co-expression on overall survival in patients with PD-1 inhibitors.

Abbreviations: PD-1, programmed death 1; PD-L1, programmed death ligand 1; SNX20, sorting nexin 20.